SecBot SecBot

KYNB

KYNTRA BIO, INC.
Nasdaq· Pharmaceutical Preparations· CIK 0000921299 Biotech & Drug Discovery
$4.49 −0.09 (−1.97%)
Oct 26 4:00 PM ET · prev $4.58
Market cap
$21.1M
Nano cap
Consensus
Buy
80% Buy or better · 10 analysts
Median target
$38.00
+746% · range $35.00–43.00
Next earnings
Nov 9
in 14 days · EPS est. −$3.33
1 year
−59.6%
from $11.12 · Oct 27
30 days
−34.9%
from $6.90
52-week range
$4.49–11.12
at the low
Avg volume 20D
24.8K
Oct 5 spike 88.3K
Short interest
100.0K
≈2.5% of shares · −0.7%
Days to cover
3.7
at average volume
Insider net
+$19.9K
1 buyer · 0 sellers · 12 mo
New fund stakes
0
Q2 2026 13F · 0 exits
SecBot read BEARISH 3 reports · 90 days
Balance 1 bearish · 0 bullish · 2 neutral oldest → newest, height = score
Avg score ·High conf. 3/3 ·Next Earnings date, Nov 9, 2026
Strongest BEARISH Kyntra Bio received a delisting determination from Nasdaq on September 30, 2026, for failing to comply with…
All reports →

Price

Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.

Signal stack

Where each data set points today.

  • InsidersBULLISH

    1 insider bought $19.9K at an average $7.09. No open-market sales. Price is 37% below their cost.

  • InstitutionsMIXED

    Q2 2026: 0 added (0 new), 1 trimmed or exited.

  • AnalystsBULLISH

    8 of 10 rate it Buy or better. Every target is above the price.

  • EstimatesFLAT

    Current-quarter EPS estimate −$3.385 → −$3.335 over 90 days. 0 up, 2 down in 30 days.

  • Short sellersSTEADY

    Short interest −0.7% to 100.0K shares. 3.7 days to cover, ≈2.5% of shares.

  • TrendDOWNTREND

    35% below its 50-day average. New closing low $4.49 on Oct 26.

Who's buying

13F· Q2 2026
0
new positions
0
exits
FundMoveSharesValue
UBS Group AGTRIM7,857$59.3K
UBS Group AGDOUBLED27,591$187.1K
MORGAN STANLEYNEAR_EXIT488$3.3K
OSAIC HOLDINGS, INC.ADD180$1.2K
TWO SIGMA INVESTMENTS, LPADD61,211$537.4K
MARSHALL WACE, LLPTRIM32,502$285.4K
Squarepoint Ops LLCTRIM12,186$107.0K
MORGAN STANLEYDOUBLED5,924$52.0K

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

10 analysts
Buy 80% rate it Buy or better
Strong Buy3Buy5Hold2Sell0Strong Sell0
12-month targets · 4 analysts

Price is below the lowest target. Median implies +746%.Targets as of Oct 26, 2026.

Recent actions
DateFirmActionRating
Oct 13, 2026Maxim Group
INITIATE
INITIATEBuy
Sep 17, 2026Lake Street
INITIATE
INITIATEBuy
Sep 1, 2026HC Wainwright & Co.
REITERATE
REITERATEBuy
Jul 7, 2026Oppenheimer
INITIATE
INITIATEOutperform
Jun 9, 2026Rodman & Renshaw
INITIATE
INITIATEBuy

Insider ledger

Form 4
$19.9K
bought · 1 insider
$0
sold · 0 insiders
−36.7%
vs their $7.09 cost
DateInsiderTypeValue
Oct 1, 2026
Singer Andrew E.
Director
AWARD14,000 sh
Sep 6, 2026
Wettig Thane
CEO
TAX W/H$1.8K
Sep 6, 2026
DeLucia David
Chief Financial Officer
TAX W/H$188.10
Jun 12, 2026
EDWARDS JEFFREY L
Director
AWARD7,000 sh
Jun 12, 2026
Kauffman Michael
Director
AWARD7,000 sh
Jun 12, 2026
Schoeneck James A
Director
AWARD7,000 sh
Jun 12, 2026
Ho Maykin
Director
AWARD7,000 sh
Jun 6, 2026
Wettig Thane
CEO
TAX W/H$1.3K

Earnings setup

Estimates
Nov 9
reports in 14 days
−$3.33
EPS estimate, this quarter
+1%
estimate change, 90 days
0↑ 2↓
revisions, 30 days
Current-quarter EPS estimate
PeriodEPS est.Range30D rev.Revenue
Current Q-$3.33-$3.75–-$2.92-0.2%$1.7M
Next Q-$3.46-$4.04–-$2.89+1.0%$2.3M
Current FY-$12.41-$12.41–-$12.41+9.7%$6.4M
Next FY-$14.23-$16.45–-$12.01-24.4%$7.3M

Short side

FINRA· Sep 30, 2026
100,040
shares short
-0.7%
vs prior settlement
3.7
days to cover
≈2.5%
of shares outstanding
Trading halts
Sep 10, 2026Volatility PauseResumed
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Oct 6, 2026 SEC
Andrew E. Singer filed a Form 3 initial statement of beneficial ownership with Kyntra Bio, Inc., indicating he has…
3 — Impact 2/10
Oct 6, 2026 SEC
Kyntra Bio received a delisting determination from Nasdaq on September 30, 2026, for failing to comply with Listing…
8-K — Impact 8/10
Oct 1, 2026 SEC
Kyntra Bio appointed Andrew E. Singer as a Class III director and Audit Committee member effective October 1, 2026…
8-K — Impact 2/10
Oct 1, 2026 Other
Kyntra Bio Appoints Andrew E. Singer, MBA to its Board of Directors
SAN FRANCISCO, Oct. 01, 2026 (GLOBE NEWSWIRE) -- Kyntra Bio (Nasdaq: KYNB) today announced the appoi
Oct 1, 2026 Insider
Singer Andrew E. was granted 14,000 shares
Director
Sep 6, 2026 Insider
Wettig Thane surrendered for taxes 209 shares
CEO @ $8.55 ($1.8K)
Sep 6, 2026 Insider
DeLucia David surrendered for taxes 22 shares
Chief Financial Officer @ $8.55 ($188.10)
Jun 30, 2026 Inst.
UBS Group AG — TRIM
7,857 shares ($59.3K)
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
Upcoming
Nov 9, 2026
Earnings date
KYNB Q3 2026 Earnings After Market Close — 2026-11-09
Recent
Oct 1, 2026
Press release
Kyntra Bio Appoints Andrew E. Singer, MBA to its Board of Directors
SAN FRANCISCO, Oct. 01, 2026 (GLOBE NEWSWIRE) -- Kyntra Bio (Nasdaq: KYNB) today announced the appointment of Andrew E. Singer, MBA to its Board of…
Sep 10, 2026
Trading halt
Halt Resumed: KYNB — trading resumed after LUDP (Volatility Trading Pause)
Halted 2026-09-10T17:23:26.000Z | Resumed 2026-09-10T17:28:26.000Z
Sep 10, 2026
Trading halt
Trading Halt: KYNB — LUDP (Volatility Trading Pause)
Kyntra Bio Cmn | Market: NASDAQ | Code: LUDP — Volatility Trading Pause
Aug 31, 2026
Restatement
Kyntra Bio Continues Balance Sheet Transformation with Material Reduction of Royalty Financing Obligation
SAN FRANCISCO, Aug. 31, 2026 (GLOBE NEWSWIRE) -- Kyntra Bio (Nasdaq: KYNB) today announced the signing of an amendment and restatement of its…
Aug 13, 2026
Earnings
Kyntra Bio Reports Second Quarter 2026 Financial Results and Provides Business Update
SAN FRANCISCO, Aug. 13, 2026 (GLOBE NEWSWIRE) -- Kyntra Bio (Nasdaq: KYNB) today reported financial results for the second quarter 2026 and provided…

SecBot reports

5 filings · 1 press release · 0 bullish · 1 bearish · 1 mixed · 3 neutral
All KYNB filing & press-release reports (6)